A method of prophylaxis or treatment of inflammatory conditions, including, but not limited to, intestinal epithelial inflammation due to intestine-specific conditions (e.g., Crohn's disease or ulcerative colitis) or systemic causes of inflammation (e.g., endotoxemia, sepsis, hemorrhagic shock/resuscitation or pancreatitis) is disclosed. In the method of the invention, an affected patient is administered a therapeutically effective amount of a composition including an NAD-related compound, in a form that is accessible to a receptor molecule, conveyed in a pharmaceutically acceptable carrier vehicle. NAD-related compounds include nicotinamide adenine dinucleotide (NAD.sup.+), cyclic adenosine diphosphate ribose (cADPR), or functionally equivalent analogues, derivatives, metabolites or agonists thereof or prodrugs therefor. Also disclosed are ex vivo and in vivo assay methods to test candidate compounds for activity, kits for carrying out the therapeutic methods or the assay methods of the invention and articles of manufacture that include compositions for use in the methods of the invention and instructions for the use thereof.

University of Pittsburgh - of the Commonwealth System of Higher Education

Extracellular NAD.sup.+ and cADPR as potent anti-inflammatory agents

A phosphorylated A.sub.2A receptor agonist providing agonist properties on the A.sub.2A receptor after dephosphorylation the phosphorylated A.sub.2A receptor agonist comprises a ribosyl moiety and a purine moiety and being phosphorylated at the 5'-position of the ribose moiety except adenosine monophosphate (AMP), adenosine diphosphate (ADP) or adenosine triphosphate (ATP), a medicament containing the compound of the invention including ADP and the use of the compound of the invention including ATP and ADP for several medical indications e.g. inflammatory events. In particular, compounds of formula (I) are also disclosed. ##STR00001##

adenosine diphosphate/zápal

Extracellular NAD.sup.+ and cADPR as potent anti-inflammatory agents

Phosphorylated A2A receptor agonists

Najkompletnejšia databáza liečivých bylín podporovaná vedou